CRISPR Timeline CRISPR Update
Posted: December 17, 2017 at 10:41 pm
1987: CRISPR repeats were observed in bacterial genomes. The authors concluded, no sequence homologous to these has been found elsewhere in procaryotes, and the biological significance of these sequences is not known. Ishino et al. J. Bacteriology (1987) 169:5429-5433. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC213968/
2002: The term CRISPR was coined to describe the repetitive repeats observed in bacterial and archaeal genomes. Genes usually found associated with the CRISPR repeats were identified and named CRISPR Associated Proteins or Cas. Jansen et al. Mol. Microbiology. (2002) 43:1565-1575. http://www.ncbi.nlm.nih.gov/pubmed/11952905
2005: CRISPR spacer sequences were matched to foreign DNA. Bolotin et al. Microbiology (2005) 151:2551-2561. http://www.ncbi.nlm.nih.gov/pubmed/16079334
2006: CRISPR was first proposed to be a bacterial adaptive immune system. Makarova et al. Biol Direct (2006) 1:7. http://www.ncbi.nlm.nih.gov/pubmed/16545108.
2007: CRISPR loci were found to impart phage resistance in bacteria. It was determined that CRISPR sequences together with the Cas genes impart resistance and that resistance to specific phages was determined by the spacer sequences found between CRISPR repeats. Barrangou et al. Science. (2007) 315:1709-1712. http://www.ncbi.nlm.nih.gov/pubmed/17379808
2009: RNA guided RNA cleavage is first described. Hale et al. RNA (2008) 2:2572-2579. http://www.ncbi.nlm.nih.gov/pubmed/18971321
2010: The CRISPR/Cas system was identified as a bacterial and archeal immune system that targets and cleaves phage DNA. This system was found to be dependent on the bacteria containing CRISPR spacer sequences that match the phage DNA. Additionally researchers discovered that new spacer sequences could be inserted into the bacterial/archeal chromosome making the CRISPR/Cas system an adaptive immune system. Garneau et al. Nature. (2010) 468:67-71. http://www.ncbi.nlm.nih.gov/pubmed/21048762
2011: Cas9 from Streptococcus pyogenes was found to associate with two RNA molecules coined crRNA and tracrRNA and that all these components are required for protection against phage infection. Deltcheva et al. Nature (2011) 471:602-607. http://www.ncbi.nlm.nih.gov/pubmed/21455174
2012: Cas9 was found to be an endonuclease capable of introducing DSB in DNA and that this process is dependent on complementary binding of the crRNA to the target DNA. Two nuclease domains were found in Cas9 with the HNH domain cleaving the complementary strand and the RuvC-like domain cutting the non-complementary strand. Jinek et al. Science (2012) 337:816-821. http://www.ncbi.nlm.nih.gov/pubmed/22745249
2013: The CRISPR/Cas9 system was used to edit targeted genes in both human and mouse cells using designed crRNA sequences. Cong et al. Science (2013) 339:819-823. http://www.ncbi.nlm.nih.gov/pubmed/23287718
First use in plants. Li et al. Nat Biotechnol (2013) 8:688-691. http://www.ncbi.nlm.nih.gov/pubmed/23929339
Also first use in plants ? Nekrasov et al. Nat Biotechnol (2013) 8:691-693. http://www.ncbi.nlm.nih.gov/pubmed/23929340.
2014: The crystal structure of Cas9 complexed with both gRNA and targeted DNA was elucidated. Nishimasu et al. Cell (2014) 156:935-949. http://www.ncbi.nlm.nih.gov/pubmed/24529477
PAMs are identified as a key component of DNA target integration. Anders et al. Nature (2014) 513:569-573. http://www.ncbi.nlm.nih.gov/pubmed/25079318
sgRNA and Cas9 are directly delivered into cells without the use of a vector intermediate. Ramakrishna et al. Genome Res (2014) 24:1020-1027. http://www.ncbi.nlm.nih.gov/pubmed/24696462
2015: CRISPR/Cas9 was used to edit tri-chromosomal pre-implantation human embryos. Researchers attempted to repair the HBB locuswhich, when mutated, results in -thalassemia blood disorders. The researchers were unable to effectively repair the mutated locus and many off-target cleavages were observed. Liang et al. Protein and Cell (2015) 6:363-372. http://www.ncbi.nlm.nih.gov/pubmed/25894090
2015: An international moratorium is called for making heritable changes to the human genome using gene editing.At an international meeting convened by the National Academy of Science of the United States, the Institute of Medicine, The Chinese Academy of Sciences, and the Royal Society of London scientists called for a moratorium on making inheritable changes to the human genome. None of these groups have regulatory authority to prevent such research from taking place, however previous moratoriums where widely accepted in 1975 when an international group met in California to discuss gene editing in all species.http://www.nytimes.com/2015/12/04/science/crispr-cas9-human-genome-editing-moratorium.html?_r=0
2016: The USDA determines CRISPR/Cas9 edited crops will not be regulated as GMOs. Due to the lack of foreign DNA and the inability to distinguish CRISPR modified crops from those created by traditional plant breeding the USDA has determined that gene edited crops will not be regulated like traditional GMOs.http://www.nature.com/news/gene-edited-crispr-mushroom-escapes-us-regulation-1.19754
2016: The first human trial to use CRISPR gene editing gets approval from the NIH. A National Institute of Health advisory committee approved the use of CRISPR/Cas9 gene editing in a cancer therapy trial. The treatment will use CRISPR/Cas9 technology to edit the patients own T cells to target cancer.http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-us-panel-1.20137
Read the original here:
CRISPR Timeline CRISPR Update
- What's the Latest in CRISPR Gene-Editing Technology? - Technology Networks - March 12th, 2024
- In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis | Oncogene - Nature.com - March 12th, 2024
- Investigating the mechanisms underlying resistance to chemoterapy and to CRISPR-Cas9 in cancer cell lines ... - Nature.com - March 12th, 2024
- Here's Why CRISPR Therapeutics Stock Climbed 34% in February - The Motley Fool - March 12th, 2024
- SXSW Panel Recap: The First CRISPR Foods Have Arrived - Austin Chronicle - March 12th, 2024
- CRISPR-Cas systems: Overview, innovations and applications in human ... - March 4th, 2024
- CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst - The Motley Fool - March 4th, 2024
- Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold - The Motley Fool - March 4th, 2024
- MEGA-CRISPR tool gives a power boost to cancer-fighting cells - Nature.com - February 23rd, 2024
- 3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential - InvestorPlace - February 23rd, 2024
- CRISPR 'will provide cures for genetic diseases that were incurable before,' says renowned biochemist Virginijus iknys - Livescience.com - February 23rd, 2024
- Opinion: The Promise and Challenges of CRISPR-Based Treatments - BioSpace - February 23rd, 2024
- There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump - Simply Wall St - February 23rd, 2024
- Move over, CRISPR: RNA-editing therapies pick up steam - Nature.com - February 23rd, 2024
- If You Invested $10000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today - The Motley Fool - February 23rd, 2024
- CRISPR Therapeutics Joins Rank Of Stocks With 95-Plus Composite Rating - Investor's Business Daily - February 23rd, 2024
- CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month High on Better-Than-Expected Earnings - AmericanBankingNEWS - February 23rd, 2024
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire - February 23rd, 2024
- CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance - February 23rd, 2024
- Advancements in RNA for HIV Treatment: CRISPR Cas9, mRNA Therapeutics, and Next-Generation Sequencing ... - Medriva - February 23rd, 2024
- Intellia Therapeutics Charges Ahead: A Glimpse into the Future of CRISPR-Based Therapies - BNN Breaking - February 23rd, 2024
- The FDA Approved The First CRISPR-Based Therapy. What's Next? - Science Friday - February 5th, 2024
- Using CRISPR technology, researchers succeed in growing tomatoes that consume less water without compromising yield - Phys.org - February 5th, 2024
- CRISPR-Cas9 gene-editing tool repairs defective T cells to treat rare hereditary disease - News-Medical.Net - February 5th, 2024
- New CRISPR Technology Increases Recognition of Cancer Cells by the Immune System - Inside Precision Medicine - February 5th, 2024
- Is CRISPR Therapeutics a Buy in the New Bull Market? - The Motley Fool - February 5th, 2024
- Stocks Flashing Renewed Technical Strength: CRISPR Therapeutics - Investor's Business Daily - February 5th, 2024
- AI at Davos, new CRISPR therapies and health tech's bad marketing - Marketplace - January 20th, 2024
- FDA expands use of newly approved CRISPR therapy - Axios - January 20th, 2024
- CRISPR-based therapy receives expanded approval for beta thalassemia - STAT - January 20th, 2024
- CRISPR Therapeutics And Vertex's CRISPR Breakthrough: How And Why They Got There First - Scrip - January 20th, 2024
- Pharmalittle: We're reading about a CRISPR approval, selling meds directly to patients, and more - STAT - January 20th, 2024
- Here's Why CRISPR Therapeutics Stock Rose 54% Last Year - The Motley Fool - January 20th, 2024
- Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease - MedCity News - January 20th, 2024
- Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval - geneonline - January 20th, 2024
- What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024? - The Motley Fool - January 20th, 2024
- First FDA-approved CRISPR-based gene therapy cleared for 2nd indication - LabPulse - January 20th, 2024
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY ... - GlobeNewswire - January 20th, 2024
- CRISPR Gene Editing And Its Role In Hematology | TheHealthSite.com - TheHealthSite - January 20th, 2024
- Doudna institute hatches plan to 'cure hundreds of diseases' left behind by CRISPR revolution - STAT - January 11th, 2024
- Discover the recent progress of nonviral delivery carriers for CRISPR/Cas9 systems - News-Medical.Net - January 11th, 2024
- How CRISPR could yield the next blockbuster crop - Nature.com - January 11th, 2024
- Weight-loss drugs, malaria vaccines and more: CRISPR innovations headline the science breakthroughs of 2023 - Genetic Literacy Project - January 11th, 2024
- CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook - GlobeNewswire - January 11th, 2024
- CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha - January 11th, 2024
- CRISPR to be used to genetically modify crops - FoodNavigator.com - January 11th, 2024
- Casgevy approval unlikely to be followed up by another CRISPR drug in near future - BioPharma-Reporter.com - January 11th, 2024
- Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell ... - Business Wire - January 11th, 2024
- The Science Behind CRISPR: Germline Genome Editing and Its Applications - Medriva - January 11th, 2024
- Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics - The Motley Fool - January 11th, 2024
- Revolutionizing acne treatment with CRISPR technology - Labiotech.eu - January 11th, 2024
- What Is CRISPR Gene Editing and How Does It Work? - December 25th, 2023
- This first CRISPR treatment is just the beginning. Heres what's next - Fast Company - December 25th, 2023
- The Age of Crispr Medicine Is Here - WIRED - December 25th, 2023
- 6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy - Yahoo Finance - December 25th, 2023
- Crispr Therapeutics Medical Chief Morrow to Resign - The Wall Street Journal - December 25th, 2023
- Crispr Therapeutics chief medical officer is resigning - MarketWatch - December 25th, 2023
- 3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow - Yahoo Finance - December 25th, 2023
- CAR T Therapy May Cause Rare Cancer & How CRISPR Could Be The Solution - Forbes - December 25th, 2023
- CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief - InvestorPlace - December 25th, 2023
- With the promise of saving millions of lives, CRISPR medicine is born - EL PAS USA - December 25th, 2023
- Casgevy: the world's first CRISPR therapy - Epigram - December 25th, 2023
- The Basics of CRISPR Gene Editing - Cleveland Clinic Health Essentials - November 27th, 2023
- Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing - November 27th, 2023
- What is CRISPR gene editing, and how does it work? - The Conversation - October 16th, 2023
- What is CRISPR/Cas9? - PMC - National Center for Biotechnology Information - October 16th, 2023
- CRISPR, 10 Years On: Learning to Rewrite the Code of Life - April 26th, 2023
- What Is CRISPR, and Why Is It So Important? - Scientific American - March 23rd, 2023
- Global CRISPR Technology Market Is Projected To Grow At A 22% Rate Through The Forecast Period - EIN News - March 14th, 2023
- What is CRISPR and why is it controversial? | CNN - February 2nd, 2023
- CRISPR | Description, Technology, Uses, & Ethical Concerns - February 2nd, 2023
- In vivo CRISPR screening reveals nutrient signaling processes ... - PubMed - December 12th, 2022
- What is CRISPR? | New Scientist - October 16th, 2022
- CRISPR-Cas9 Structures and Mechanisms - PubMed - October 16th, 2022
- A CRISPR cure for HIV? Gene-editing technology may be able stop viral replication in its tracks and wipe out infections - Genetic Literacy Project - October 16th, 2022
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 16th, 2022
- More Foods Will Be Gene-Edited Than You Think - The Epoch Times - October 16th, 2022
- What is CRISPR? - MD Anderson Cancer Center - September 21st, 2022
- CRISPR infusion eliminates swelling in those with rare genetic disease - Science - September 21st, 2022
- Crispr Therapeutics becomes the latest biotech to open in the Seaport - The Boston Globe - September 21st, 2022